Extraintestinal Manifestations in Patients with Inflammatory Bowel Disease: Study Based on the ENEIDA Registry.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Algaba Alicia, Guerra Iván, Ricart Elena, Iglesias Eva, Mañosa Miriam, Gisbert Javier P, Guardiola Jordi, Mínguez Miguel, Castro Beatriz, de Francisco Ruth, Nos Pilar, Bertoletti Federico, Mesonero Francisco, Barrio Jesús, Martín-Arranz María Dolores, Calvet Xavier, García-López Santiago, Sicilia Beatriz, Alcaín Gillermo, Esteve María, Márquez Lucía, Piqueras Marta, Jiménez Laura, Perez-Calle José L, Bujanda Luis, García-Sepulcre Mariana, Fernández Alejandra, Moraleja Irene, Lorente Rufo Humberto, García-Bosch Orlando, Lambán Ana, Blázquez Isabel, Rodríguez Esther, Huguet José M, Lucendo Alfredo J, Almela Pedro, Busquets David, Ramírez de la Piscina Patricia, Pérez Marcela, Domenech Eugeni, Bermejo Fernando, Spanish GETECCU Group (ENEIDA Project)
Аннотация
AIMS: Our aim was to analyse the prevalence and characteristics of EIMs in patients with IBD and to identify the possible risk factors associated with the development of EIMs in the largest series published to date.
METHODS: Observational, cross-sectional study including patients from the Spanish ENEIDA registry promoted by GETECCU. We retrospectively identified all cases of EIMs in the ENEIDA registry until January 2018.
RESULTS: The study included 31,077 patients, 5779 of whom had at least one EIM (global prevalence 19%; 95% CI 18.2-19.0). Among the different types of EIMs, rheumatic manifestations had a prevalence of 13% (95% CI 12.9-13.7; 63% of EIMs), with a prevalence of 5% (95% CI 4.7-5.2) for mucocutaneous manifestations, 2.1% (95% CI 1.9-2.2) for ocular manifestations, and 0.7% (95% CI 0.6-0.8) for hepatobiliary manifestations. The multivariable analysis showed that the type of IBD (Crohn's disease, p < 0.001), gender (female, p < 0.001), the need for an immunomodulator (p < 0.001) or biologic drugs (p < 0.001), a previous family history of IBD (p < 0.001), and an extensive location of IBD (p < 0.001) were risk factors for the presence of EIMs.
CONCLUSIONS: One-fifth of patients with IBD may have associated EIMs, with rheumatic manifestations as the most frequent (> 60% of EIMs). Female patients with severe Crohn's disease represent the group with the highest risk of developing EIMs. These patients should therefore be specially monitored and referred to the corresponding specialist when suggestive symptoms appear.